Clinical Trial: PfSPZ-LARC2 in Women of Child-bearing Potential (WOCBP)

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07675785) titled 'PfSPZ-LARC2 in Women of Child-bearing Potential (WOCBP)' on June 17.

Brief Summary: A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy WOCBP, who are on pregnancy prevention during vaccination, but report plans to become pregnant in the near future.

Participants will be randomized into two arms. Arm 1: (n= 150) will receive 3 doses of PfSPZ-LARC2 Vaccine (2x10^5 PfSPZ) via direct venous inoculation (DVI) at 1, 6, 29 days.

Arm 2: (n= 150) will receive 3 doses ...